Sort   by:  
 Page size 
ProteomicsPhosphatidic acid features double membrane vesicle formation during Hepatitis C and SARS-CoV-2 infection
Double membrane vesicles (DMVs) are used as replication organelles by pathogenic RNA viruses such as hepatitis C virus (HCV) and severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Viral DMVs are morphologically analogous to DMVs formed during autophagy, and although the proteins required...
ORGANISM(S): Homo sapiens (Human) 
2022-01-24 | PXD029692 | Pride
Dmvs Lipid phosphatidic acid Sars-cov-2 Hepatitis c 
ProteomicsSARS-CoV-2 Spike Protein and Murine Hepatitis Virus Inhib-its S. pneumoniae and S. aureus Biofilms
The recovery of other pathogens in COVID-19 patients has been reported. The presence of either co-infection or superinfection with bacterial pathogens was associated with poor outcomes, including increased mortality. The recognition of possibility of SARS-CoV-2 co-infection is important as it enable...
ORGANISM(S): Streptococcus pneumoniae Staphylococcus aureus 
2022-04-04 | PXD029967 | Pride
Streptococcus pneumoniae  staphylococcus aureus  biofilm  sars-cov-2  spike protein 
ProteomicsImmunological and Metabolic Characteristics of the Omicron Variants Infection
The Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in November 2021 in South Africa, has initiated the 5th wave of global pandemics. Here, we systemically examined immunological and metabolic characteristics of Omicron variants infection. We found ...
ORGANISM(S): Cercopithecus aethiops (Green monkey) (Grivet) 
2023-03-11 | PXD037955 | Pride
Cos7 cell hla class ι hepatitis b virus and sars-cov-2 peptides 
ProteomicsThe Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections
The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that th...
ORGANISM(S): Mus musculus (Mouse) Betacoronavirus 
2026-09-07 | PXD073706 | Pride
Remdesivir  ivermectin  combination therapy  repurposed drugs  murine hepatitis virus  proteomics  transcriptomics 
UnknownToward a SARS-CoV-2 VLP Vaccine: HBc/G as a Carrier for SARS-CoV-2 Spike RBM and Nucleocapsid Protein-Derived Peptides.
Not available
S-EPMC10974900 | biostudies-literature
UnknownExploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches.
Not available
S-EPMC7894964 | biostudies-literature
ProteomicsIdentification of complex of Paraprevotella clara 00502 protein and human PRSS2
00502 protein derived from Paraprevotella clara, as well as mixture of 00502 protein and human PRSS2 were analyzed by Native-PAGE. The observed bands were cut out and digested in-gel. The digested peptides were analyzed by DDA-MS using Q Exactive HF-X .
ORGANISM(S): Paraprevotella Clara 
2022-06-29 | PXD032242 | JPOST Repository
ProteomicsLC-MS/MS proteomic analysis of pharyngeal swabs and plasma from MHV-infected and uninfected mice
Recent developments have broadened our perception of SARS-CoV-2, indicating its capability to affect the body systemically beyond its initial recognition as a mere respiratory pathogen. However, the pathways of its widespread are not well-understood. Employing a dual-modality approach, we integrated...
ORGANISM(S): Severe acute respiratory syndrome coronavirus 2 Mus musculus (Mouse) 
2024-12-11 | PXD054355 | Pride
Pharyngeal swabs Mus musculus Mhv Plasma Lc-m/ms 
UnknownIdentification of virus-specific B-cell epitopes by convalescent plasma from COVID-19 patients.
Not available
S-EPMC9630139 | biostudies-literature
UnknownPeptides for Vaccine Development.
Not available
S-EPMC9384901 | biostudies-literature
Sort   by:  
 Page size